Brand Name(s) in US
ChemicalBook > CAS DataBase List > Pradofloxacin

Pradofloxacin

Brand Name(s) in US
Product Name
Pradofloxacin
CAS No.
195532-12-8
Chemical Name
Pradofloxacin
Synonyms
Pudofloxacin;Pradofloxacin;Pradofloxacin (Veraflox);8-cyano-1-cyclopropyl-7-((1S,6S)-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid;8-Cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic acid;3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-
CBNumber
CB12515848
Molecular Formula
C21H21FN4O3
Formula Weight
396.41
MOL File
195532-12-8.mol
More
Less

Pradofloxacin Property

Melting point:
246-248°C
Boiling point:
664.5±55.0 °C(Predicted)
Density 
1.50±0.1 g/cm3(Predicted)
pka
6.38±0.50(Predicted)
CAS DataBase Reference
195532-12-8
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Warning
Hazard statements

H302Harmful if swallowed

H341Suspected of causing genetic defects

Precautionary statements

P201Obtain special instructions before use.

P202Do not handle until all safety precautions have been read and understood.

P264Wash hands thoroughly after handling.

P264Wash skin thouroughly after handling.

P270Do not eat, drink or smoke when using this product.

P281Use personal protective equipment as required.

P301+P312IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.

P308+P313IF exposed or concerned: Get medical advice/attention.

P330Rinse mouth.

P405Store locked up.

P501Dispose of contents/container to..…

More
Less

Pradofloxacin Chemical Properties,Usage,Production

Brand Name(s) in US

Veraflox

Uses

Pradofloxacin is a novel fluoroquinolone antibiotic. An antimicrobial agent.

Indications

Dogs: Pradofloxacin is a novel third-generation fluoroquinolone currently approved in Europe to treat canine wound infections and superficial and deep pyoderma associated with susceptible strains of Staphylococcus pseudinterme- dius. However, it has shown lower minimal inhibitory concentration (MIC) when compared to various fluoroquinolones for the following organisms: Bordetella, Escherichia coli, Enterococcus, Klebsiella pneumonia, Staphylococcus, Staphy- lococcus pseudintermedius, Streptococcus, Pseudomonas, Proteus, Mycoplasma, Salmonella, and Pasteurella. Moreover, in contrast to other fluoroquinolones, pradofloxacin has shown excellent in-vitro activity against anaerobic bacteria isolated from dogs and cats. Pradofloxacin, concurrently with topical therapy, may also be of benefit for treatment of chronic ear infections, particularly otitis media, caused by susceptible organisms such as Pseudomonas. However, tissue concentration is not known for the external or middle ear, and this indication is controversial with unpredictable efficacy.
Note: The authors do not recommend the use of fluoroquinolones as first-line therapy for pyoderma. Fluoroquinolones should be considered primarily for chronic deep pyodermas associated with extensive scar tissue, because of their excellent tissue penetration. Antibiotic selection, however, should be based on culture and susceptibility results.

Mechanism of action

Pradofloxacin is a third-generation fluoroquinolone that inhibits DNA supercoiling and synthesis by inhibition of bacterial DNA gyrase and topoisomerase IV. Because of these two fluoroquinolone targets, development of resistance is less likely than with other fluoroquinolones. Similarly to other fluoroquinolones, pradofloxacin accumulates inside inflammatory cells, in particular in macrophages.

Side effects

Dogs: pradofloxacin is generally well tolerated, but it may cause nausea, vomiting, diarrhea, soft stools, lethargy. These signs are typically mild and transient. It can induce seizure when administered at high doses.

Drug interactions

Antacids containing divalent or trivalent cations (e.g., Mg++, Al++, Ca++), iron, zinc: decrease pradofloxacin absorption; separate administration of these products and pradofloxacin by at least 2 hours
Aminoglycosides, third-generation cephalosporins, extended spectrum penicillins: drug synergism may occur, especially against Pseudomonas
Digoxin: may increase oral bioavailability of digoxin Cyclosporine: may reduce the metabolism of cyclosporine
Methotrexate, theophylline: may increase the blood levels of these drugs
Nitrofurantoin: may reduce the antimicrobial effect of fluoroquinolones

Pradofloxacin Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Pradofloxacin Suppliers

Protheragen-ING
Tel
+16313385890
Email
info@protheragen-ing.com
Country
United States
ProdList
3868
Advantage
58

195532-12-8, PradofloxacinRelated Search:


  • 8-Cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic acid
  • 8-cyano-1-cyclopropyl-7-((1S,6S)-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
  • Pradofloxacin
  • Pradofloxacin (Veraflox)
  • 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-
  • Pudofloxacin
  • 195532-12-8